76.82
price up icon0.08%   0.06
after-market アフターアワーズ: 76.82
loading
前日終値:
$76.76
開ける:
$77.1
24時間の取引高:
1.29M
Relative Volume:
0.58
時価総額:
$12.69B
収益:
$943.38M
当期純損益:
$-380.99M
株価収益率:
-31.14
EPS:
-2.4667
ネットキャッシュフロー:
$-325.67M
1週間 パフォーマンス:
+2.45%
1か月 パフォーマンス:
+7.91%
6か月 パフォーマンス:
+6.12%
1年 パフォーマンス:
+170.68%
1日の値動き範囲:
Value
$75.77
$77.18
1週間の範囲:
Value
$74.53
$77.38
52週間の値動き範囲:
Value
$27.57
$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
名前
Ionis Pharmaceuticals Inc
Name
セクター
Healthcare (1112)
Name
電話
(760) 931-9200
Name
住所
2855 GAZELLE COURT, CARLSBAD, CA
Name
職員
1,402
Name
Twitter
@ionispharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IONS icon
IONS
Ionis Pharmaceuticals Inc
76.82 12.68B 943.38M -380.99M -325.67M -2.4667
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
441.70 113.01B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
753.93 79.87B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
840.87 51.51B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
333.39 45.29B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
319.94 34.41B 5.36B 287.73M 924.18M 2.5229

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-10 再開されました Raymond James Outperform
2026-01-28 再開されました Barclays Overweight
2025-10-08 アップグレード JP Morgan Neutral → Overweight
2025-09-26 アップグレード Goldman Sell → Neutral
2025-09-03 アップグレード BMO Capital Markets Market Perform → Outperform
2025-07-31 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-07-01 アップグレード Barclays Equal Weight → Overweight
2025-04-07 開始されました H.C. Wainwright Buy
2025-03-31 開始されました Redburn Atlantic Neutral
2024-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-07-24 アップグレード Leerink Partners Market Perform → Outperform
2024-07-16 再開されました Jefferies Buy
2024-06-14 アップグレード Bernstein Underperform → Mkt Perform
2024-04-10 アップグレード Wolfe Research Peer Perform → Outperform
2024-01-02 アップグレード BofA Securities Neutral → Buy
2023-10-23 アップグレード BofA Securities Underperform → Neutral
2023-09-29 開始されました Raymond James Strong Buy
2023-07-31 アップグレード Citigroup Neutral → Buy
2023-06-07 再開されました Piper Sandler Overweight
2023-05-04 アップグレード Citigroup Sell → Neutral
2023-03-21 開始されました Bernstein Underperform
2022-12-21 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-09-09 再開されました Morgan Stanley Overweight
2022-07-18 再開されました Oppenheimer Outperform
2022-03-31 再開されました Piper Sandler Overweight
2022-03-01 開始されました Citigroup Sell
2022-03-01 開始されました Guggenheim Buy
2022-02-01 ダウングレード BofA Securities Buy → Underperform
2021-12-14 アップグレード William Blair Mkt Perform → Outperform
2021-05-07 アップグレード UBS Sell → Neutral
2021-03-01 アップグレード Barclays Underweight → Equal Weight
2020-12-16 開始されました UBS Sell
2020-12-15 アップグレード Cowen Market Perform → Outperform
2020-09-14 再開されました JP Morgan Neutral
2020-09-02 開始されました The Benchmark Company Hold
2020-06-01 再開されました Oppenheimer Outperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-05 開始されました Citigroup Buy
2019-12-13 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-11-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-09-10 アップグレード Bernstein Mkt Perform → Outperform
2018-08-08 繰り返されました Stifel Hold
2018-08-07 繰り返されました Stifel Hold
2018-05-08 ダウングレード Evercore ISI Outperform → In-line
2017-10-06 再開されました Goldman Sell
2017-08-17 開始されました Evercore ISI Outperform
2017-08-09 繰り返されました Stifel Hold
2017-03-10 ダウングレード Goldman Neutral → Sell
2016-12-28 繰り返されました BMO Capital Markets Outperform
2016-12-27 繰り返されました Leerink Partners Mkt Perform
すべてを表示

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
10:40 AM

Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com

10:40 AM
pulisher
07:06 AM

Ionis to hold first quarter 2026 financial results webcast - The Joplin Globe

07:06 AM
pulisher
04:10 AM

Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

04:10 AM
pulisher
04:07 AM

Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus

04:07 AM
pulisher
04:06 AM

Ionis Pharmaceuticals Inc at BMO Capital Markets Growth & ESG Conference (Virtual) Transcript - GuruFocus

04:06 AM
pulisher
Apr 13, 2026

Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals - Yahoo Finance

Apr 13, 2026
pulisher
Apr 10, 2026

(IONS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Apr 10, 2026
pulisher
Apr 10, 2026

Ionis Pharmaceuticals (IONS) Receives Outperform Rating with Ele - GuruFocus

Apr 10, 2026
pulisher
Apr 10, 2026

Ionis Pharmaceuticals Inc : Raymond James Res - Moomoo

Apr 10, 2026
pulisher
Apr 10, 2026

Winners Losers: Is Ionis Pharmaceuticals Inc a top pick in the sector2026 Market Outlook & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Apr 10, 2026
pulisher
Apr 09, 2026

Ionis Pharmaceuticals (IONS) Receives Updated Analyst Rating fro - GuruFocus

Apr 09, 2026
pulisher
Apr 09, 2026

BofA Securities Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating - Moomoo

Apr 09, 2026
pulisher
Apr 09, 2026

IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill

Apr 09, 2026
pulisher
Apr 08, 2026

Antisense Oligonucleotides Market 2026-2033 | US$ 5,286.96 - openPR.com

Apr 08, 2026
pulisher
Apr 07, 2026

Will Ionis Pharmaceuticals Inc benefit from sector rotation2026 Price Targets & AI Enhanced Market Trend Forecasts - baoquankhu1.vn

Apr 07, 2026
pulisher
Apr 07, 2026

Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors - TipRanks

Apr 07, 2026
pulisher
Apr 06, 2026

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - GlobeNewswire Inc.

Apr 06, 2026
pulisher
Apr 05, 2026

Treasury Yields: Can Ionis Pharmaceuticals Inc outperform in the next rallyQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn

Apr 05, 2026
pulisher
Apr 04, 2026

Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN

Apr 04, 2026
pulisher
Apr 04, 2026

IONS Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026
pulisher
Apr 04, 2026

IONS PE Ratio & Valuation, Is IONS Overvalued - Intellectia AI

Apr 04, 2026
pulisher
Apr 04, 2026

IONS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026
pulisher
Apr 04, 2026

Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market - MSN

Apr 04, 2026
pulisher
Apr 04, 2026

Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by SG Americas Securities LLC - MarketBeat

Apr 04, 2026
pulisher
Apr 03, 2026

Retinitis Pigmentosa Market to Reach US$ 26.2 Billion by 2032 - openPR.com

Apr 03, 2026
pulisher
Apr 03, 2026

Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com

Apr 03, 2026
pulisher
Apr 03, 2026

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 03, 2026
pulisher
Apr 02, 2026

Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmac - gurufocus.com

Apr 02, 2026
pulisher
Apr 02, 2026

Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmaceuticals Inc (IONS) - gurufocus.com

Apr 02, 2026
pulisher
Apr 02, 2026

Devers, Ionis Pharmaceuticals EVP, sells $458,613 in IONS stock By Investing.com - Investing.com Canada

Apr 02, 2026
pulisher
Apr 02, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 6,193 Shares - marketbeat.com

Apr 02, 2026
pulisher
Apr 02, 2026

J. Safra Sarasin Holding AG Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Apr 02, 2026
pulisher
Apr 02, 2026

ETF Watch: Can Ionis Pharmaceuticals Inc weather a recessionWeekly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn

Apr 02, 2026
pulisher
Apr 01, 2026

Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com

Apr 01, 2026
pulisher
Mar 31, 2026

Form 144 | Ionis Pharmaceuticals(IONS.US) Director Proposes to Sell 5.47 Million in Common Stocks - Moomoo

Mar 31, 2026
pulisher
Mar 31, 2026

H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada

Mar 31, 2026
pulisher
Mar 31, 2026

Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS - marketbeat.com

Mar 31, 2026
pulisher
Mar 30, 2026

The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following FDA Priority Review For Zilganersen - Sahm

Mar 30, 2026
pulisher
Mar 28, 2026

FDA Priority Review Puts Ionis Zilganersen At Center Of Rare-Disease Story - Yahoo Finance

Mar 28, 2026
pulisher
Mar 27, 2026

Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report? - Yahoo Finance

Mar 27, 2026
pulisher
Mar 27, 2026

Vanguard disaggregates holdings; reports 0 IONS shares (IONS) - Stock Titan

Mar 27, 2026
pulisher
Mar 27, 2026

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail

Mar 27, 2026
pulisher
Mar 27, 2026

Is It Time To Reassess Ionis Pharmaceuticals (IONS) After Its Strong One Year Share Price Run? - Sahm

Mar 27, 2026
pulisher
Mar 26, 2026

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Ionis Pharmaceuticals (IONS) - The Globe and Mail

Mar 26, 2026
pulisher
Mar 26, 2026

Ionis Cuts Tryngolza Price Ahead Of Big New Indication - insights.citeline.com

Mar 26, 2026
pulisher
Mar 26, 2026

Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market - Benzinga

Mar 26, 2026
pulisher
Mar 26, 2026

Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106 - Yahoo Finance

Mar 26, 2026
pulisher
Mar 26, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $106.00 at Barclays - MarketBeat

Mar 26, 2026
pulisher
Mar 26, 2026

Barclays Raises Price Target for Ionis Pharmaceuticals (IONS) to $106 | IONS Stock News - GuruFocus

Mar 26, 2026
pulisher
Mar 26, 2026

Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart

Mar 26, 2026
pulisher
Mar 26, 2026

What is HC Wainwright's Estimate for IONS FY2027 Earnings? - marketbeat.com

Mar 26, 2026

Ionis Pharmaceuticals Inc (IONS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$54.26
price up icon 2.69%
$48.70
price down icon 0.25%
$99.47
price up icon 1.08%
$152.54
price up icon 3.76%
$146.74
price down icon 4.34%
ONC ONC
$319.94
price up icon 3.21%
大文字化:     |  ボリューム (24 時間):